close
About Ubix
Ubix Therapeutics develops novel anti-cancer drugs based on Degraducer® platform technology.
Degraducer® is a powerful, next-generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable.
We are developing novel anti-cancer therapies based on conscientious research and understanding of the human immune system and target proteins. Our goal is to increase life span and improve quality of life for affected patients.
Debiopharm
In June 2021, Ubix Therapeutics and Debiopharm entered into a co-research agreement combining two novel proprietary technologies.
Read More
NeoImmunetch
In March 2020, Ubix Therapeutics entered into an Exclusive License Agreement with NeoImmuneTech.
Read More
Kyungpook National University
We are continuing close research collaborations with Kyungpook National University based on their top-level in-silico screening technologies.
Gachon University
Through collaboration with Gachon University, we are securing structural information of target proteins and designing new drugs.
POSTECH
With POSTECH's proprietary HTS system, we are discovering groundbreaking ligand hits for previously undruggable target proteins.
KRICT • KRIBB
We have received a technological transfer of the novel E3 ligase binder from KRICT and KRIBB. Our collaboration with two organizations continues to improve Degraducer® and develop Degraducer® applied therapeutics.